Sodium Stibogluconate
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Sodium Stibogluconate: From Leishmaniasis to Drug-Induced Osteoporosis
One-Sentence Summary
Sodium stibogluconate is a pentavalent antimonial compound whose only well-established clinical use is the treatment of leishmaniasis. The TxGNN model predicts it may be effective for Drug-Induced Osteoporosis, but this prediction is currently supported by 0 clinical trials and 0 publications — the score comes purely from knowledge graph topology, not verified biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Leishmaniasis (known clinical use; not confirmed via local regulatory licenses, as the drug is not registered locally) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.56% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for sodium stibogluconate (MOA: Data Gap). Based on known clinical information, this drug is a pentavalent antimonial compound used primarily for the treatment of leishmaniasis, a parasitic disease. Its antiparasitic mechanism has no established connection to bone metabolism, osteoclast/osteoblast regulation, or the pathophysiology of drug-induced osteoporosis.
The TxGNN prediction score is high (99.56%, ranked 7,663), but without a verifiable mechanistic pathway, this score most likely reflects knowledge graph topology (e.g., shared metabolic enzyme nodes or immune-pathway connections) rather than a genuine pharmacological relationship. The absence of any supporting clinical trials or literature further weakens confidence in this prediction — it cannot be distinguished from graph noise at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
Sodium stibogluconate is currently not marketed, with 0 registrations on file. No license records are available for review.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on TxGNN model output (L5, no clinical or literature support), and the drug’s mechanism of action, original indication confirmation, and safety profile are all currently undocumented. There is no biologically plausible pathway connecting antileishmanial activity to bone metabolism.
To proceed, the following is needed:
- TFDA/local regulatory label (warnings, contraindications) — currently blocking (DG001)
- Verified mechanism of action data from DrugBank or primary literature (DG002)
- Confirmation of original approved indication(s)
- Preclinical or mechanistic studies linking sodium stibogluconate to bone metabolism before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.